AbbVie (ABBV) IV into FDA decision on Rinvoq
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St rises as AI momentum holds heading into key earnings, Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mail
Get Alerts ABBV Hot Sheet
Price: $286.88 +0.05%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.4%
EPS Growth %: +101.1%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.4%
EPS Growth %: +101.1%
Join SI Premium – FREE
AbbVie (NYSE: ABBV) 30-day option implied volatility is at 23; compared to its 52-week range of 18 to 40 into FDA decision on Rinvoq.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IREN Limited (IREN) call put ratio 2.6 calls to 1 put as share price up 7.7%
- Seagate Technology (STX) call put ratio 2.9 calls to 1 put into quarter results
- Intel (INTC) call put ratio 2.2 call to 1 put into quarter results
Create E-mail Alert Related Categories
OptionsRelated Entities
Options, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
